Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel.

Proceedings of the National Academy of Sciences of the United States of America - 7 Jul 2020

Tan Jie, Liu Rengyun, Zhu Guangwu, Umbricht Christopher B, Xing Mingzhao

Abstract excerpt

Combination use of BRAF V600E inhibitor dabrafenib and MEK inhibitor trametinib has become a standard treatment for human cancers harboring BRAF V600E. Its anticancer efficacies vary, however, with dramatic efficacy in some patients and drug resistance/tumor recurrence in others, which is poorly understood. Using thyroid cancer, melanoma, and colon cancer cell models, we showed that dabrafenib and trametinib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colonic Neoplasms
Share to Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinases

Share to Oximes

Share to Pyridones

Share to Pyrimidinones

Share to Telomerase

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 32561648
DOI: 10.1073/pnas.2004707117
PMCID: PMC7355024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TERT promoter mutation determines apoptotic and therapeutic responses of BRAF-mutant cancers to BRAF and MEK inhibitors: Achilles Heel.PMID 32561648Read ↗

TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.Semantic proximity Read ↗

TERT Promoter Revertant Mutation Inhibits Melanoma Growth through Intrinsic ApoptosisSemantic proximity Read ↗

Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.Semantic proximity Read ↗

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In VitroSemantic proximity Read ↗

SNAI2 cooperates with MEK1/2 and HDACs to suppress BIM- and BMF-dependent apoptosis in <i>TERT</i> promoter mutant cancersSemantic proximity Read ↗

Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma.Semantic proximity Read ↗

Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism.Semantic proximity Read ↗

Therapeutic targeting of FOS in mutant TERT cancers through removing TERT suppression of apoptosis via regulating survivin and TRAIL-R2.Semantic proximity Read ↗

Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.Semantic proximity Read ↗

Telomerase reactivation induces progression of mouse Braf <sup>V600E</sup> -driven thyroid cancers without telomere lengtheningSemantic proximity Read ↗

Mesenchymal and MAPK Expression Signatures Associate with Telomerase Promoter Mutations in Multiple Cancers.Semantic proximity Read ↗

Trametinib in the treatment of multiple malignancies harboring MEK1 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.